On Tuesday, the European Parliament's committee members have recently endorsed a significant legislative overhaul aimed at enhancing the attractiveness of the European continent for pharmaceutical companies. However, this move has sparked concerns among drug companies, fearing the changes might have the opposite effect. Specifically, the reform includes a proposal to modify the current data protection period for new medicines, reducing it from eight years to potentially 7.5 years. This decision is part of a broader EU pharma reform initiative, which has successfully passed a major hurdle, despite the pharmaceutical industry's apprehensions regarding the adjustments to data protection proposals.